The Geonomics Podcast

Andrew Han (ex-GenomWeb) and I recorded our first podcast last week, breaking down AGBT 2026. Andy was on the ground on the ground in Orlando, and I was camping out by the pool at the Biltmore Miami, providing remote moral support 🤣   My biggest takeaway: the sequencing market is splitting into two camps. One side wants beautiful, integrated, clinical-grade systems. The other side is saying: just...

Many of us grew up with the scent of Johnson's Baby Powder as one of our earliest memories. Trusted by moms since 1894, the product has built an extraordinary trusted brand (rooted in deep scent associations with motherly love) for one of the world's largest pharmaceutical companies, Johnson and Johnson. But in 2018 Reuters published an investigation showing J&J had known for decades t...

It was amazing to have the opportunity to talk NGS with Matt Sause, the CEO of Roche Diagnostics, the world's largest clinical diagnostics provider with $17B in sales. Matt's businesses range across the full spectrum of DX products and services from diabetes CGM to Foundation Medicine oncology testing. It was also great to find Josh Lauer on the call! Josh heads up the $4B (ie about the sa...

Pierre Arsene, CEO of liquid biopsy company Mursla Bio

I talked with Molly He and Michael Previte , founders at Element Biosciences , the day after Illumina announced it was suing Element for patent infringement. Definitely was top of mind for them, but not of course something they could opine on directly. Nevertheless provided very interesting context for the conversation, and proof in my opinion of their disruptive impact on the life science industr...

DNA sequencing swept the world in two waves: first of all Sanger sequencing, developed in the '70s and the underpinning of the 2000's Human Genome Project, and then NGS which drove the cost of a human genome sequence from billions to thousand of dollars from 2006 onwards. Echoing that history, protein sequencing is now in its first innings, dominated by technologies that provide proteomic...

Geonomics Podcast Newsbreak! A 15 minute interview with Ultima Genomics CEO Gilad Almogy on why the hell he's giving away 3 Trillion free sequencing reads 🤯🤯🤯 The program is called "Count on Us" (get it? 🤣) and I we talk about: - Motivation was initiated in response to the current uncertainties in NIH funding. Recognizing the stress and potential budget freezes faced by researche...

Excited to announce a new episode of the Geonomics Podcast : part 2 of my interview with the fabulous Susan Tousi, CEO of DELFI Diagnostics . In this episode we discuss her unique career path starting out as a Penn State engineering grad then leading Eastman Kodak Company 's printer business to leading Illumina 's R&D and then commercial units and now CEO of Delfi. Susan deep-dives on...

Early this week I got to sit with Element Biosciences founders Molly He (CEO) and Michael Previte (CTO) in their comically big board room and we had a great in-depth conversation about their careers and building Element. All up a fantastic discussion and in my humble 😏 opinion an entire MBA packed into one hour of easy listening! 1. How the hell did you two get here? - Molly’s personality: compet...

For this episode of the Geonomics Podcast I had the opportunity to interview Gilad Almogy, CEO of Ultima Genomics. Ultima has been making big waves in the NGS market by aggressively pushing down the cost curve, most recently announcing an $80 price point at AGBT. Here's what we talked about: 1. Ultima's Technology and Cost Advantages  – Whether a competitor, customer, or analyst, suggest you liste...

Really interesting roaming chat with Christian Henry, CEO of PacBio.

Genomics Star Reporters Steph Budel (DeciBio/LEK) and Jeremy Preston (Sequins/Illumina /Alex black boat survivor) interviewing movers and shakers at the bar at the Marco Island JW Marriott Tuesday evening: - Lauren Laing: Investor, Oxford Science Enterprises - Mike Previte: Element co-founder & CTO - Manoj Dadlani: Executive Chair, Cmbio - Shawn Levy: SVP Cellanome, CSO Element Enjoy!

I was thinking about who would have the most objective opinion on Roche's new NGS technology and Susan immediately jumped to mind. Her professional experience is completely unique: heading up Illumina's R&D, then heading up Illumina's commercial organization, and now CEO of one of the leading cancer screening companies, so a major NGS customer. We ended up talking for an hour, so I've decided...